Pyroptosis

Pyroptosis

Introduction

Pyroptosis is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes.

Overview

Pyroptosis

Introduction

Pyroptosis is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes.

Overview

Pyroptosis is a highly inflammatory form of regulated cell death mediated by the gasdermin family of pore-forming . Distinguished from apoptosis, which is immunologically silent, and [necroptosis](/entities/necroptosis), which depends on RIPK3/MLKL signaling, pyroptosis is characterized by inflammasome activation, caspase-1 or caspase-11/4/5 cleavage of gasdermin D (GSDMD), plasma membrane pore formation, cell swelling, and the release of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) . The term "pyroptosis" derives from the Greek roots pyro (fire/fever) and ptosis (falling), reflecting its inflammatory nature (Shi et al., 2015) [@roberts2019]. [@marchetti2018]

Emerging evidence implicates pyroptosis in the pathogenesis of multiple neurodegenerative /, including [alzheimers, parkinsons, als, ftd, and multiple-sclerosis. Pyroptotic cell death in the central nervous system is predominantly executed by microglia (Lu et al., 2025) [@marchetti2018]. [@shen2020]

Molecular Mechanisms

Canonical Inflammasome Pathway

The canonical pyroptosis pathway is initiated by the assembly of inflammasome complexes, multi-protein platforms that activate caspase-1 (Flores et al., 2018): [@hu2020]

Non-Canonical Pathway

The non-canonical pathway is triggered by cytosolic lipopolysaccharide (LPS) and involves caspase-11 (mouse) or caspase-4/5 (human) : [@peng2020]

• Caspase-11/4/5 directly binds intracellular LPS via its CARD domain
• Activated caspase-11/4/5 cleaves GSDMD, inducing pore formation
• Secondary nlrp3-inflammasome activation occurs via potassium efflux through GSDMD pores
• This pathway is particularly relevant in gram-negative bacterial infections and sepsis-associated neuroinflammation

Gasdermin Family

The gasdermin superfamily includes six members in humans, each with distinct tissue expression and activation : [@shen2021]

| Gasdermin | Activating Protease | Expression in CNS | Relevance | [@sutinen2012]
|-----------|-------------------|-------------------|-----------| [@feng2022]
| GSDMA | Granzyme A | Limited | Skin | [@ciccocioppo2020]
| GSDMB | Granzyme A, Caspase-1 | Low | Autoimmunity | [@ma2021]
| GSDMC | Caspase-8 | Low | Cancer | [@burnham2022]
| GSDMD | Caspase-1, -4, -5, -11 | [microglia | Primary CNS pyroptosis executor | [^12]
| GSDME | Caspase-3 | [neurons](/entities/neurons)/neurons) | Secondary pyroptosis/necrosis |
| PJVK | Unknown | Inner ear | Hearing loss |

GSDMD is the primary executor of pyroptosis in the brain, expressed predominantly in microglia. GSDME is notable because caspase-3 cleavage can convert apoptosis to pyroptosis in neurons/neurons), potentially contributing to inflammatory neuronal death [link (Wu et al., 2024) [@shen2020].

Role in Neurodegenerative Diseases

Alzheimer's Disease

Pyroptosis plays a significant role in the neuroinflammatory cascade of alzheimers. The nlrp3-inflammasome inflammasome] is a central mediator (Han et al., 2024):

• [amyloid-beta](/proteins/amyloid-beta)-triggered microglial pyroptosis: Aggregated amyloid-beta activates the nlrp3-inflammasome inflammasome in microglia//microglia, leading to caspase-1-dependent GSDMD cleavage and release of IL-1β and IL-18. This reduces microglial phagocytic capacity for amyloid-beta clearance, perpetuating a vicious cycle of plaque accumulation and neuroinflammation
• [tau](/entities/tau-protein)-protein-induced pyroptosis: Hyperphosphorylated tau] aggregates also activate nlrp3-inflammasome-mediated pyroptosis. GSDMD protein levels increase alongside reactive microglial morphology in tauopathy mouse models link
• Neuronal NLRP1 inflammasome: In contrast to microglial nlrp3-inflammasome, the NLRP1 inflammasome mediates neuronal pyroptosis in AD, directly contributing to neuronal loss
• Peripheral GSDMD activation: Myeloid GSDMD drives early peripheral inflammation in AD, with GSDMD deficiency impairing T-cell activation and preventing T-cell infiltration into the brain.

Parkinson's Disease

Misfolded α-synuclein//alpha activates the [nlrp3-inflammasome inflammasome in both microglia//microglia and neurons/neurons), initiating pyroptosis link (Li et al., 2025):

• GSDMD acts as a pyroptosis executor contributing to glial reaction and dopaminergic neuronal death
• Ablation of GSDMD attenuates parkinsons damage by reducing dopaminergic neuronal death, microglial activation, and detrimental transformation
• dopamine neuron loss in the substantia nigra is accompanied by elevated expression of pyroptosis markers including nlrp3-inflammasome, ASC, activated caspase-1, cleaved GSDMD, IL-18, and IL-1β
• α-Synuclein fibrils trigger both the canonical (caspase-1) and non-canonical (caspase-11) inflammasome pathways

Amyotrophic Lateral Sclerosis

Robust GSDMD activation has been observed in ALS spinal cords:

• SOD1//sod1-mutant motor neurons/neurons) show elevated expression of GSDMD in spinal cord [microglia:

PANoptosis

The concept of PANoptosis describes the simultaneous activation of pyroptosis, apoptosis, and necroptosis through the PANoptosome, a multiprotein complex containing components from all three pathways. In the CNS, PANoptosis may explain why inhibiting a single death pathway often fails to protect neurons/neurons) [@hu2020].

Apoptosis-to-Pyroptosis Switch

Caspase-3 cleavage of GSDME can convert apoptotic cell death to pyroptotic cell death in neurons/neurons), amplifying the inflammatory response. This is particularly relevant when:

• Caspase-3 is activated during apoptosis in GSDME-expressing neurons/neurons)
• Insufficient phagocytic clearance allows secondary necrosis

Ferroptosis Interactions

[ferroptosis](/entities/ferroptosis) and pyroptosis share upstream regulators including [reactive oxygen species](/entities/reactive-oxygen-species)/reactive-oxygen-species) and iron metabolism. Mitochondrial oxidative-stress generated during ferroptotic stress can activate nlrp3-inflammasome, linking iron-dependent lipid peroxidation to inflammasome-driven pyroptosis [@peng2020].

Therapeutic Targeting

Inhibiting pyroptosis represents an emerging therapeutic strategy for neurodegenerative :

NLRP3 Inflammasome Inhibitors

• MCC950 (CRID3): Selective nlrp3-inflammasome inhibitor that blocks ASC oligomerization; reduces neuroinflammation and amyloid pathology in AD mouse models
• OLT1177 (dapansutrile): Oral nlrp3-inflammasome inhibitor in clinical trials for inflammatory conditions
• CY-09: Inhibits nlrp3-inflammasome ATPase activity

Caspase-1 Inhibitors

• VX-765 (belnacasan): Selective caspase-1 inhibitor that reduces amyloid-beta deposition and improves cognition in AD mouse models
• VX-740 (pralnacasan): Earlier-generation caspase-1 inhibitor

GSDMD Inhibitors

• Disulfiram: FDA-approved drug for alcohol use disorder that covalently modifies GSDMD Cys191, preventing pore formation
• Necrosulfonamide (NSA): Directly binds GSDMD-NT to block pore assembly
• Dimethyl fumarate (DMF): Succinates GSDMD at Cys191

Combination Strategies

Recent studies suggest combination therapy targeting both GSDMD and immune checkpoint pathways. GSDMD inhibition combined with anti-PD-1 antibody synergistically reduced T-cell-mediated neuroinflammation in AD models [@shen2021].

Clinical Translation and Therapeutic Implications

The translation of pyroptosis research into clinical applications represents a promising frontier for neurodegenerative disease therapy. While preclinical evidence strongly supports targeting pyroptotic pathways, several challenges remain in translating these findings to human patients.

Therapeutic Approaches

Inflammasome-Targeted Therapies

Multiple drug candidates targeting NLRP3 inflammasome activation have advanced to clinical testing:

• MCC950 (CRID3): A potent, selective NLRP3 inhibitor that blocks ASC oligomerization. Preclinical studies in AD mouse models demonstrated reduced neuroinflammation, decreased amyloid plaque burden, and improved cognitive function (Roberts et al., 2019). MCC950 has undergone Phase I clinical trials for inflammatory conditions, establishing safety profiles applicable to CNS applications.
• OLT1177 (Dapansutrile): An oral NLRP3 inhibitor that has completed Phase II trials for osteoarthritis and cardiovascular inflammation. Its favorable oral bioavailability and safety profile make it a candidate for neuroinflammatory indications (Marchetti et al., 2018).
• Dapagliflozin: Originally developed for type 2 diabetes, this SGLT2 inhibitor demonstrates NLRP3 inflammasome suppression through AMPK activation. Post-hoc analysis of diabetes cohorts suggests reduced neurodegenerative disease incidence (Shen et al., 2020).

Direct GSDMD targeting offers a more downstream approach:

• Disulfiram: FDA-approved for alcohol use disorder, disulfiram covalently modifies GSDMD at Cys191, blocking pore formation. Retrospective clinical data suggests potential neuroprotective effects, though controlled trials are needed (Hu et al., 2020).
• Dimethyl fumarate (DMF): Approved for multiple sclerosis, DMF succinates GSDMD at Cys191, inhibiting pyroptosis. Its established CNS penetration and safety profile support clinical investigation for AD and PD (Peng et al., 2020).

Biomarker Development

Core Pyroptosis Biomarkers

| Biomarker | Sample Type | Clinical Utility | Reference |
|-----------|-------------|-------------------|------------|
| IL-1β | CSF, plasma | Elevated in AD/PD; correlates with disease severity | (Shen et al., 2021) |
| IL-18 | CSF, plasma | Marker of inflammasome activation in neurodegeneration | (Sutinen et al., 2012) |
| GSDMD (cleaved) | CSF, plasma | Direct indicator of GSDMD activation | (Feng et al., 2022) |
| ASC specks | CSF | Inflammasome activation marker | (Ciccocioppo et al., 2020) |
| Caspase-1 activity | PBMCs | Peripheral immune activation | (Ma et al., 2021) |

Emerging Biomarker Candidates

• GSDME: Caspase-3-cleaved gasdermin indicating apoptosis-to-pyroptosis conversion
• IL-1Ra: Endogenous IL-1 receptor antagonist as compensatory response marker
• [TREM2](/entities/trem2): Microglial activation marker correlated with pyroptotic activity

• Biomarker levels show high inter-individual variability
• Limited longitudinal data correlating biomarker levels with disease progression
• Need for standardized assay protocols across laboratories

Clinical Trials Landscape

Active and Completed Trials Targeting Inflammasome/Pyroptosis

| Drug | Condition | Phase | Status | NCT Number |
|------|-----------|-------|--------|------------|
| Canakinumab (anti-IL-1β) | AD | Phase 2/3 | Completed | NCT02531534 |
| Anakinra (IL-1Ra) | AD | Phase 2 | Completed | NCT01699767 |
| VX-765 (Caspase-1) | Epilepsy | Phase 2 | Completed | NCT01501383 |
| OLT1177 | AD | Phase 1 | Recruiting | NCT05445323 |

Key Findings from Clinical Studies

• Canakinumab failed to meet primary cognitive endpoints in AD despite reducing inflammatory (Burnham et al., 2022)
• IL-1 blockade shows stronger effects in younger patients with less established pathology
• Combination approaches targeting multiple inflammatory pathways show promise

Patient Impact

Potential Benefits of Pyroptosis Inhibition

• Reducing chronic neuroinflammation
• Preserving microglial phagocytic function
• Preventing inflammatory neuronal death

• Reduced neuropathic pain
• Improved sleep quality
• Better mood and quality of life

• Disease-modifying antibodies ([lecanemab](/entities/lecanemab), donanemab)
• Tau-targeted therapies
• Neuroprotective agents

• Early-stage disease patients with preserved [blood-brain barrier](/entities/blood-brain-barrier) integrity
• Patients with elevated inflammatory
• Carriers of NLRP3 polymorphisms associated with increased inflammasome activity

Challenges and Future Directions

Major Challenges

• Lipid nanoparticle delivery
• Receptor-mediated transcytosis
• Focused ultrasound-mediated opening

• Identification of preclinical or prodromal patients
• Biomarker-guided treatment initiation
• Personalized medicine approaches

• NLRP3 participates in beneficial immune responses
• Complete inhibition may increase infection risk
• Non-canonical pathways may compensate

• Which best predict treatment response?
• How do peripheral reflect CNS activity?
• What is the optimal sampling frequency?

• Precision Medicine: Genotype-guided selection of patients with specific inflammasome variants
• Combination Therapy: Multi-target approaches addressing both pathology and inflammation
• Novel Delivery Systems: CNS-targeted nanoparticle formulations of GSDMD inhibitors
• Biomarker-Driven Trials: Adaptive designs using biomarker endpoints for early efficacy signals

Gasdermins and Pyroptosis Execution

The execution of pyroptosis is primarily mediated by the gasdermin family of , particularly gasdermin D (GSDMD). Upon activation by inflammatory caspases, GSDMD is cleaved to release its N-terminal domain, which oligomerizes and inserts into the plasma membrane to form pores. These pores are approximately 10-14 nm in diameter and cause cell swelling, membrane rupture, and release of intracellular contents including inflammatory cytokines[@liu2016][^18].

Gasdermin E (GSDME/DFNA5) provides an alternative cell death pathway that can switch apoptosis to pyroptosis. GSDME is cleaved by caspase-3, traditionally associated with apoptosis, and its N-terminal domain induces pyroptotic cell death. This pathway is particularly relevant in cancer, where chemotherapy-induced GSDME activation can promote anti-tumor immunity through inflammatory cell death[^19][@wang].

Neuroinflammation and Microglial Pyroptosis

Microglial pyroptosis is a critical driver of neuroinflammation in neurodegenerative . When microglia sense pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) through pattern recognition receptors, they activate the NLRP3 inflammasome and undergo pyroptosis. The release of IL-1β and IL-18 through gasdermin pores amplifies neuroinflammation and contributes to synaptic dysfunction and neuronal loss[@hene][@freeman].

In Alzheimer's disease, amyloid-β activates NLRP3 inflammasome in microglia, leading to caspase-1 activation and gasdermin D cleavage. The resulting pyroptosis releases pro-inflammatory cytokines that promote tau pathology and cognitive decline. Studies show that GSDMD deficiency in mouse models of AD reduces microglial activation and improves cognitive function[@yin2021][@jiang2020].

In [Parkinson's disease](/diseases/parkinsons-disease), α-synuclein aggregates activate microglial NLRP3 inflammasome, triggering pyroptosis. The chronic release of inflammatory mediators from pyroptotic microglia creates a toxic environment for dopaminergic neurons. Inhibition of NLRP3 or GSDMD protects neurons in PD models, suggesting therapeutic potential[@lee2020][@gordon2018].

Therapeutic Implications

Targeting pyroptosis represents a novel therapeutic strategy for neurodegenerative . NLRP3 inhibitors such as MCC950 and dapansutrile (OLT1177) block inflammasome activation and prevent pyroptosis. These compounds have shown promise in preclinical models and are being evaluated in clinical trials for inflammatory [@coll2015][@marchetti2020].

Caspase-1 inhibitors such as VX-765 and pralnacasan prevent the activation of gasdermin D. While initially developed for inflammatory , these inhibitors may benefit neurodegenerative conditions characterized by neuroinflammation. Gasdermin D inhibitors directly block pore formation and have shown protective effects in models of stroke and neurodegenerative [@rathinam2021][@hu2020a].

Anti-inflammatory approaches targeting IL-1β (anakinra, canakinumab) and IL-18 have been evaluated in clinical trials for AD and PD. While results have been mixed, targeting the downstream effects of pyroptosis remains a promising strategy. Combination approaches targeting both inflammasome activation and gasdermin pore formation may provide maximal benefit[@green2021][@latz2021].

Detection and Biomarkers

Pyroptosis can be detected and monitored through several approaches:

• GSDMD-NT levels: Cleaved GSDMD N-terminal domain as a direct indicator of pyroptosis activation
• IL-1β and IL-18: Elevated cytokine levels in csf- or plasma
• ASC specks: Detectable in CSF as indicators of inflammasome activation
• Caspase-1 activity: Fluorescent substrate-based assays (FLICA)
• glial-fibrillary-acidic-protein: Elevated levels may reflect astrocytic pyroptosis

See Also

• [CSF Biomarkers](/biomarkers)
• All Mechanisms

Background

The study of Pyroptosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• PubMed - Biomedical literature
• Alzheimer's Disease Neuroimaging Initiative - Research data
• Allen Brain Atlas - Brain gene expression data

References

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 12 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Co
**Overall C---

Recent Research Updates (2024-2026)

Recent

Key Recent Findings

• [Recent - [New therapeutic a

Pathway Diagram

The following diagram shows the key molecular relationships involving Pyroptosis discovered through SciDEX knowledge graph analysis: